Dupilumab as a Therapeutic Option in Chronic Eustachian Tube Dysfunction and Chronic Rhinosinusitis with Nasal Polyposis: A Case-Based Observation.

BACKGROUND

To report the first documented case of complete resolution of refractory dilatory Eustachian tube dysfunction (ETD) following dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP).

METHODS

Four consecutive patients with longstanding refractory dilatory ETD, severe CRSwNP, and asthma, unresponsive to multiple sinus and mastoid surgeries, were treated with dupilumab.

RESULTS

Dupilumab resulted in complete remission of both CRSwNP and dilatory ETD symptoms within 6 weeks. Audiometry and tubomanometry confirmed restoration of middle ear function.

CONCLUSION

Dupilumab may offer a novel therapeutic option for patients with dilatory ETD associated with type 2 inflammation. Further prospective studies are needed to assess its long-term efficacy.